Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis


Brown J. W. L. , Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., ...Daha Fazla

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, cilt.321, ss.175-187, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 321 Konu: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1001/jama.2018.20588
  • Dergi Adı: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
  • Sayfa Sayıları: ss.175-187

Özet

IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.